# Anaut

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anaut

- Industry: Healthcare IT
- Headquarters: Japan
- Website: www.anaut-surg.com
- Latest round: Series B (May 13, 2026)
- Investors on record: 7

## About

Founded in 2020 and based in Tokyo Japan, Anaut Inc. d.b.a Anaut develops advanced surgical assistance technologies, focusing on enhancing surgical outcomes through its EUREKA AI system, which provides real-time physiological data analysis for surgical procedures. Anaut specializes in surgical assistance technologies. The founder's history information is not available. Anaut specializes in advanced surgical assistance technologies, primarily through its flagship product, the EUREKA AI system. This state-of-the-art platform analyzes complex internal physiological data in real-time, enhancing the surgical process by providing surgeons with precise, individualized visualizations of a patient's unique anatomical structures during operations. EUREKA leverages deep learning from extensive surgical video datasets, continually improving its accuracy and expanding its application to various surgical fields, including thoracic, abdominal, and pelvic surgeries. The company aims to deliver unprecedented safety and reliability to all patients requiring surgical intervention, positioning itself as a crucial partner for surgeons in both Japan and international markets. The end users of these technologies include hospitals, surgical centers, and medical professionals who seek to enhance surgical outcomes and patient safety. Anaut generates revenue through a straightforward transaction structure involving B2B sales to healthcare institutions and practitioners. The company offers its surgical assistance systems under both medical and educational versions, catering to different segments within the healthcare market. Clients engage with Anaut via direct partnerships, where they acquire licenses or subscriptions for the EUREKA AI system to integrate it into their surgical protocols. The pricing structure reflects the high value of advanced technological solutions in surgery, with potential tiered pricing based on the extent of features and support services offered. The educational version may also create additional revenue streams, targeting medical schools and training programs that require advanced surgical education tools. Anaut plans to design and launch new products aimed at enhancing their EUREKA AI system's capabilities, although specific release dates are not available. The company targets expansion into international markets, particularly in regions with growing demand for advanced surgical technologies. In May 2026, Anaut raised an undisclosed amount in series B funding led by Nomura SPARX Investment with participation from Japan Bank for International Cooperation, JICN, Vision Incubate,  Beyond Next Ventures, ANRI and KSP. The company plans to use May 2026 funds to accelerate overseas expansion, advance R&D including new business launches, and strengthen product distribution and market reach.

## Funding rounds

- Series B, May 13, 2026 — Japan Bank for International Cooperation, ANRI, KSP, Beyond Next Ventures, Nomura SPARX Investment, JICN, Vision Incubate

## Investors

- Japan Bank for International Cooperation — Series B
- ANRI (https://capitalatlas.ai/funds/anri) — Series B
- KSP (https://capitalatlas.ai/funds/ksp) — Series B
- Beyond Next Ventures (https://capitalatlas.ai/funds/beyond-next-ventures) — Series B
- Nomura SPARX Investment (https://capitalatlas.ai/funds/nomura-sparx-investment) — Series B
- JICN — Series B
- Vision Incubate (https://capitalatlas.ai/funds/vision-incubate) — Series B